Highlights Ipsen

Equities

Real-time Euronext Paris Other stock markets 10:34:43 2024-07-03 am EDT			5-day change	1st Jan Change
112.7 ^EUR	-0.97%		-1.92%	+4.36%

Jul. 02	Ipsen Expands Partnership with Exelixis for Cabometyx	MT
Jul. 02	Ipsen extends collaboration with Exelixis	CF

Ipsen Expands Partnership with Exelixis for Cabometyx	Jul. 02	MT
Ipsen extends collaboration with Exelixis	Jul. 02	CF
IPSEN : UBS remains positive ahead of quarterly results	Jun. 26	CF
Ipsen: share price soars, UBS confirms its recommendation	Jun. 12	CF
IPSEN : UBS remains Buy after FDA approval	Jun. 12	CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis	Jun. 11	CI
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug	Jun. 10	RE
US FDA approves Genfit and Ipsen's liver disease drug	Jun. 10	RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics	Jun. 07	MT
Ipsen: research partnership with Marengo extended	Jun. 07	CF
Ipsen: new positive data in PBC	Jun. 05	CF
Ipsen: mandate to an ISP for share buybacks	Jun. 03	CF
Ipsen: new employee shareholding operation	May. 31	CF
Ex-dividend day for final dividend	May. 29	FA
Ipsen S.A. Approves Dividend, Payable on 3 June 2024	May. 28	CI
IPSEN : Better-than-expected Q1; guidance unchanged	Apr. 24
Ipsen: sales up 11% in Q1	Apr. 24	CF
Ipsen Teams Up with Skyhawk Therapeutics on Study of RNA Modulator for Rare Neurological Diseases	Apr. 22	MT
Ipsen: collaboration agreement with Skyhawk	Apr. 22	CF
Ipsen and Skyhawk Therapeutics Announces RNA Targeting Research Collaboration in Rare Neurological Diseases	Apr. 22	CI

No results for this search

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 10:50 am EDT